Mutabilis opens medicinal chemistry department
Mutabilis, a biopharmaceutical company focused on new therapies against infectious diseases, has opened a medicinal chemistry department at the company's new facility in Biocitech, the technology park recently created on the former Aventis site in Romainville near Paris. The new location is now the company headquarters.
Mutabilis, a biopharmaceutical company focused on new therapies against infectious diseases, has opened a medicinal chemistry department at the company's new facility in Biocitech, the technology park recently created on the former Aventis site in Romainville near Paris. The new location is now the company headquarters.
The new medicinal chemistry department has eight staff as well as a 600m2 state-of-the-art laboratory. This includes P2 labs for handling virulent disease strains. In addition, the company benefits from the biotech-friendly environment and services available at the technology park.
"Mutabilis' move to Biocitech is an important milestone in the company's growth," said Sonia Escaich, Mutabilis' chairman and chief scientific officer. "Our €8m Series B funding last year included the specific objective of creating an international class medicinal chemistry team. Now that we have this team and the new labs, Mutabilis can handle the whole discovery process for innovative anti-infection therapies using bacterial DNA analysis."